Escalating Irinotecan (CPT-11) Administered 24 Hours Prior To Gemcitabine In Patients With Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Sep 2010
At a glance
- Drugs Gemcitabine (Primary) ; Irinotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 24 Sep 2010 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 30 Sep 2005 New trial record.